Melanoma Trials

To go back to the main page, click here

S.No.	Drug Name	Biological Name	Developer	Current Development Phase	Additional Information	Start Date	Completion Date	Source
11	-	IMF-001	ImmunoFrontier, Inc.	I	The purpose of this study is assess the safety of administering repeated doses of IMF-001, a vaccine, to patients with solid tumors that express NY-ESO-1 antigen. If the vaccine is therapeutically useful, a second goal is to establish the maximum therapeutic dose to treat patients with NY-ESO-1 positive cancers.	2010	2011	Source
12	-	Lipovaxin-MM	Lipotek Pty Ltd	I	The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body’s ability to destroy cancer cells in patients with metastatic melanoma.	2009	2011	Source
13	-	PSMA/PRAME	MannKind Corporation	I	Completed The present clinical trial is a dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on a large number of solid cancers.	2007	2009	Source
14	-	MKC1106-MT, MKCC1106-MT	Mannkind Corporation	I	A dose comparison of a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanomas.	2008	2010	Source
15	-	MKC1106-MT	Mannkind Corporation	II	The clinical trial is evaluating a multi-component active immunotherapy designed to stimulate an immune reaction to specific tumor associated antigens which are highly expressed on melanoma	2010	2012	Source
16	-	V934/V935	Merck	I	Completed. This is a two-part study to test the safety, tolerability, and immune response for V934/V935 vaccine using a new prime-boost regimen in participants with selected solid tumors.	2008	2011	Source
17	-	Pegylated Interferon-Alpha 2b	NewLink Genetics	II	The purpose of this study is to determine the safety of giving subjects with advanced, recurrent or refractory melanoma the HyperAcute® Melanoma vaccine with a variant of a drug, called Interferon (PEG-Intron®) that is specially formulated to be given on a weekly basis (instead of daily).	2008	2011	Source
18	-	-	Sanofi-Aventis	II	Terminated Objective was: To evaluate the clinical activity of the vaccine regimen, as indicated by progression-free survival versus the clinical activity of the reference treatment.	2008	2010	Source
19	-	AdhTAP	TapImmune	Preclinical	-	-	-	-
20	-	Dacarbazine (DTIC), Temozolomide (TMZ)	Vical/AnGes	III	Approval possibly by 2013	2006	2012	Source

To go back to the main page, click here